Evolving treatment paradigm in metastatic non clear cell renal cell carcinoma [0.03%]
转移性非透明细胞肾癌的治疗模式演变
Shuchi Gulati,Errol Philip,Sabrina Salgia et al.
Shuchi Gulati et al.
The treatment landscape for renal cell cancer (RCC) has evolved tremendously over the last two decades. Treatment algorithms have shifted from the highly toxic drugs with marginal benefit to better tolerated and more effective targeted ther...
Diabetes mellitus type 2 is associated with increased tumor expression of programmed death-ligand 1 (PD-L1) in surgically resected non-small cell lung cancer-A matched case-control study [0.03%]
一项配对病例对照研究：2型糖尿病与非小细胞肺癌手术切除标本中的肿瘤程序性死亡配体1(PD-L1)高表达有关
Christopher A Febres-Aldana,Robert Poppiti,John M Varlotto et al.
Christopher A Febres-Aldana et al.
Objectives: Programmed death-ligand 1 (PD-L1) expression is a biomarker for cancer immunotherapy. Diabetes mellitus type-2 is a comorbid disease associated with adverse outcomes in Non-Small Cell Lung Cancer (NSCLC). We a...
Emmelyn Buenacosa Nepucpan,Danielle Benedict Sacdalan
Emmelyn Buenacosa Nepucpan
Primary soft tissue giant cell tumors are rare. Although these tumors resemble their osseous counterparts, sequencing studies have suggested that these two may be genetically distinct. Treatment guidelines are less clear for this tumor type...
The role of active surveillance and cytoreductive nephrectomy in metastatic renal cell carcinoma [0.03%]
主动监测和细胞减少性肾切除术在转移性肾细胞癌中的作用
Amanda Nizam,Jonah A Schindelheim,Moshe C Ornstein
Amanda Nizam
Treatment of metastatic renal cell carcinoma (mRCC) has been revolutionized by an expanding armamentarium of systemic therapies, which have resulted in improved patient outcomes. Multimodal approaches that include cytoreductive nephrectomy ...
Reduced delays in diagnostic pathways for non-small cell lung cancer after local and National initiatives [0.03%]
局部和国家倡议后非小细胞肺癌诊断途径延迟减少
Dan Laerum,Odd Terje Brustugun,Frode Gallefoss et al.
Dan Laerum et al.
Objectives: Patients with non-small cell lung cancer (NSCLC) may experience progression and stage shift due to delays in a complex and time-consuming diagnostic work-up. We have analyzed the impact of both a local and nat...
Latest advances in management of small cell lung cancer and other neuroendocrine tumors of the lung [0.03%]
小细胞肺癌和其他肺神经内分泌肿瘤治疗的最新进展
Hussein A Assi,Sukhmani K Padda
Hussein A Assi
Neuroendocrine tumors of the lung are a diverse group of diseases with distinct pathological, molecular, and clinical characteristics. The most recent World Health Organization (WHO) classification identifies two types of high-grade neuroen...
The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testing [0.03%]
尿路上皮癌生殖细胞变异的现状：基因检测的意义
Panagiotis J Vlachostergios,Bishoy M Faltas,Maria I Carlo et al.
Panagiotis J Vlachostergios et al.
Urothelial carcinoma (UC) of the bladder and upper tract (ureter, renal pelvis) is one of the most frequently occurring malignancies. While the majority of UC are chemically induced by smoking, accumulating evidence from genetic studies hav...
Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches [0.03%]
转移性去势抵抗性前列腺癌的新兴治疗方式：免疫疗法、PARP抑制剂和PSMA靶向疗法
Catherine Handy Marshall,Emmanuel S Antonarakis
Catherine Handy Marshall
Recently there has been an explosion of new agents being investigated for the treatment of prostate cancer. These modalities represent new therapies aimed at old targets, and new therapies addressing new targets. This review will highlight ...
Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values [0.03%]
转移性透明细胞肾癌治疗的近期进展：使用第二代p值的证据审查
Jacob J Adashek,Giannicola Genovese,Nizar M Tannir et al.
Jacob J Adashek et al.
The therapeutic options for advanced or metastatic renal cell carcinoma (mRCC) have drastically evolved over the past 20 years. High-dose interleukin-2 (HD IL-2), which led to durable complete responses in a small fraction of patients by ac...
Adherence to guidelines for baseline staging in newly diagnosed localized breast cancer [0.03%]
新诊断的局限性乳腺癌初始评估指南依从性的研究
Liliana DeMiglio,Victoria Murdoch,Jessica Ivison et al.
Liliana DeMiglio et al.
Rationale, aims, and objectives: Different health agencies in Canada including Cancer Care Ontario (CCO) have developed guidelines for the baseline staging of newly diagnosed breast cancer patients but adherence to them i...